Skip to content
Sign in
Family officeBacked 1 network startup

Biothom

Finnish family office investing in life sciences; joined StemSight's €2.3M seed extension in 2025.

Finland
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
3most often with Business Finland

How they invest

Life sciences (biotech) via family-office capital; the record has no thesis beyond StemSight (ophthalmic cell therapy for the cornea).

Stage and ticket

Not specified; seed extension participation.

Geography

Finland.

What makes them say yes

  • Finnish life-science company
  • Seed-stage biotech with syndicate (Voima, Business Finland)
  • Inferred: ophthalmology/regenerative medicine

Red flags

  • No Finnish link
  • Non-life-science

Sectors

  • Biotech & life sciences

Stages

Not published

Geographies

  • Finland

How to approach

Ask StemSight's founders (network peer) for an intro.

Portfolio

1 network startup · no other company

One network deal (StemSight seed extension, Feb 2025).

Gaps in the portfolio

  • No other Finnish life-science company in the network

Network startups

  • StemSightSWC 2026 Finalist

    Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

    Finland · Biotech & life sciences

    • seed extension · 1 Feb 2025Source

Network startups that fit

3 analysed

University of Liverpool spin-off making corneal topography portable with OCUTOP, a handheld device matching reference machines.

UK portable corneal topography diagnostics with first clinicians: cornea adjacency to StemSight, but UK-based and medtech.

20%confidence

Evidence from the records

  • “Portable ophthalmic diagnostics (corneal topography)”
  • “Seed”
Intro path
StemSight (Biothom portfolio, cornea peer)
First step
Explore a StemSight-OCUWELL clinical link before pitching Biothom.

HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

Polymer therapeutics in ophthalmology with a first-in-human trial: ophthalmic overlap, but Series A in China.

10%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Business Finland, Stephen Industries, and Voima Ventures

Sources

  1. 1en.ain.ua/2025/02/13/stemsight-raises-eur23-m
  2. 2nordic9.com/companies/biothom-investor9605828855/

Profile compiled from public sources. Unknown fields are left empty rather than estimated.